Linzagolix (Yselty) with hormonal add-back therapy will offer a new at-home treatment option for some women in England with ...

Abbott and Neurocrine Biosciences have entered into a collaboration to develop and commercialize elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that has recently completed a Phase ...

GnRH agonists can delay the bone age advancement and subsequently improve the final adult height. Method: Sixty eight girls with central precocious puberty and early puberty with a mean age of 9 ...

USA-based Medicus Pharma (Nasdaq: MDCX) has agreed to acquire UK firm Antev for around $75 million in a share exchange deal.

Degarelix therefore provides a new, effective ADT with a different and direct mode of action compared with GnRH agonists. In contrast to agonists, where concomitant antiandrogens are needed at the ...

The two FDA-approved oral GnRH antagonists – AbbVie and Neurocrine Biosciences' Oriahnn (elagolix) and Myovant's Pfizer-partnered Myfembree (relugolix) – are both combined with hormonal drugs.

There is no cure, and current treatment relies on pain relief and hormonal treatment, with injectable gonadotropin-releasing hormone (GnRH) agonists and surgery generally used as second-line options.

The study investigators identified 24 prospective trials with 2,850 patients. The median patient age ranged between 59 and 77 years. Overall, testosterone recovery, defined at 240 ng/dL, was observed ...